Pub Date : 2025-06-26Epub Date: 2025-05-23DOI: 10.5692/clinicalneurol.cn-002104
Akiyuki Hiraga
When presenting a case from your clinical experience at a conference, your slides need to be easy to understand and effective. To create good slides, follow these six key points: (i) Reduce the amount of information on each slide; (ii) Use a font with good visibility; (iii) Use only two colours (main and accent) other than white, black, and grey - avoid using primary colours; (iv) Use discussion slides with tables or illustrations, rather than a bulleted list; (v) Follow these four design principles: alignment, repetition, proximity, and contrast - ensure appropriate margins; and (vi) Ensure that the conclusion slide conveys a clear message to the audience. Additionally, by using Morph Transition, you can deliver your presentation without a pointer, making it more dynamic and visually engaging.
{"title":"[Summarising a case you experienced: how to create understandable and effective slides].","authors":"Akiyuki Hiraga","doi":"10.5692/clinicalneurol.cn-002104","DOIUrl":"10.5692/clinicalneurol.cn-002104","url":null,"abstract":"<p><p>When presenting a case from your clinical experience at a conference, your slides need to be easy to understand and effective. To create good slides, follow these six key points: (i) Reduce the amount of information on each slide; (ii) Use a font with good visibility; (iii) Use only two colours (main and accent) other than white, black, and grey - avoid using primary colours; (iv) Use discussion slides with tables or illustrations, rather than a bulleted list; (v) Follow these four design principles: alignment, repetition, proximity, and contrast - ensure appropriate margins; and (vi) Ensure that the conclusion slide conveys a clear message to the audience. Additionally, by using Morph Transition, you can deliver your presentation without a pointer, making it more dynamic and visually engaging.</p>","PeriodicalId":39292,"journal":{"name":"Clinical Neurology","volume":" ","pages":"459-467"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Syphilitic gumma is a rare manifestation of neurosyphilis that can cause mass lesions in the central nervous system. We present an atypical case of a 53-year-old man presenting with syphilitic gummas affecting both the brain and spinal cord. The patient presented with right facial numbness, worsening back pain, gait disturbances, and lower-limb weakness. Serological tests were positive for syphilis, and cerebrospinal fluid analysis showed elevated cell count, protein concentration, and positive syphilis tests. Brain and spinal cord MRI revealed dural-based enhancing mass lesions in the right middle cerebellar peduncle and conus medullaris. The patient underwent posterior decompression and biopsy of the conus medullaris. Histopathological findings excluded malignancy and were consistent with syphilitic gumma. The patient received intravenous benzylpenicillin, followed by oral amoxicillin, resulting in partial improvement of neurological symptoms and gradual regression of the lesions on follow-up MRI. This case highlights the importance of considering syphilitic gumma in the differential diagnosis of intracranial and spinal cord lesions in patients with syphilis. Prompt antibiotic treatment and serial MRI imaging are crucial for managing this condition.
{"title":"Syphilitic gummas affecting brain and spinal cord: a case report.","authors":"Hikari Kondo, Toru Watanabe, Kazuyoshi Kobayashi, Amane Araki, Kazuhiro Hara, Keizo Yasui","doi":"10.5692/clinicalneurol.cn-002105","DOIUrl":"10.5692/clinicalneurol.cn-002105","url":null,"abstract":"<p><p>Syphilitic gumma is a rare manifestation of neurosyphilis that can cause mass lesions in the central nervous system. We present an atypical case of a 53-year-old man presenting with syphilitic gummas affecting both the brain and spinal cord. The patient presented with right facial numbness, worsening back pain, gait disturbances, and lower-limb weakness. Serological tests were positive for syphilis, and cerebrospinal fluid analysis showed elevated cell count, protein concentration, and positive syphilis tests. Brain and spinal cord MRI revealed dural-based enhancing mass lesions in the right middle cerebellar peduncle and conus medullaris. The patient underwent posterior decompression and biopsy of the conus medullaris. Histopathological findings excluded malignancy and were consistent with syphilitic gumma. The patient received intravenous benzylpenicillin, followed by oral amoxicillin, resulting in partial improvement of neurological symptoms and gradual regression of the lesions on follow-up MRI. This case highlights the importance of considering syphilitic gumma in the differential diagnosis of intracranial and spinal cord lesions in patients with syphilis. Prompt antibiotic treatment and serial MRI imaging are crucial for managing this condition.</p>","PeriodicalId":39292,"journal":{"name":"Clinical Neurology","volume":" ","pages":"453-458"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-27Epub Date: 2025-04-25DOI: 10.5692/clinicalneurol.cn-002070
Daisuke Danno, Paul Shanahan, Manjit Matharu
Objective: Although population-based studies of hemiplegic migraine (HM) exist, large-scale clinic-based studies focusing on the detailed clinical characteristics of HM have not been reported. This study aims to define the clinical characteristics of HM in a tertiary care headache centre.
Methods: A retrospective analysis was conducted based on the medical records of HM patients.
Patients: This study included 163 consecutive HM patients who visited the National Hospital for Neurology and Neurosurgery between 2006 and 2013.
Results: According to the diagnostic criteria of International Classification of Headache Disorders (ICHD-3β), 142 patients were diagnosed with HM. Although 21 patients did not satisfy the diagnostic criteria, migrainous headaches with repetitive hemiparesis were reported and other disorders were excluded, hence these patients were clinically diagnosed with HM. The temporal progression of aura symptoms was atypical in 40 patients. The median duration of hemiparesis was 24 hours (interquartile range: 3-60 hours) which was far longer than that of previous population-based studies. The lifetime experience of an episode of motor aura exceeding 72 hours was reported in 51.6%. Hemiparesis was observed without full recovery in 9 patients (5.5%).
Conclusions: In many HM patients, the temporal progression of aura symptoms was diverse compared to typical descriptions in the literature, and the aura symptoms sustained longer than reported in the population-based study.
{"title":"Clinical characteristics of hemiplegic migraine: a clinical study of 163 cases in a tertiary care headache centre.","authors":"Daisuke Danno, Paul Shanahan, Manjit Matharu","doi":"10.5692/clinicalneurol.cn-002070","DOIUrl":"10.5692/clinicalneurol.cn-002070","url":null,"abstract":"<p><strong>Objective: </strong>Although population-based studies of hemiplegic migraine (HM) exist, large-scale clinic-based studies focusing on the detailed clinical characteristics of HM have not been reported. This study aims to define the clinical characteristics of HM in a tertiary care headache centre.</p><p><strong>Methods: </strong>A retrospective analysis was conducted based on the medical records of HM patients.</p><p><strong>Patients: </strong>This study included 163 consecutive HM patients who visited the National Hospital for Neurology and Neurosurgery between 2006 and 2013.</p><p><strong>Results: </strong>According to the diagnostic criteria of International Classification of Headache Disorders (ICHD-3β), 142 patients were diagnosed with HM. Although 21 patients did not satisfy the diagnostic criteria, migrainous headaches with repetitive hemiparesis were reported and other disorders were excluded, hence these patients were clinically diagnosed with HM. The temporal progression of aura symptoms was atypical in 40 patients. The median duration of hemiparesis was 24 hours (interquartile range: 3-60 hours) which was far longer than that of previous population-based studies. The lifetime experience of an episode of motor aura exceeding 72 hours was reported in 51.6%. Hemiparesis was observed without full recovery in 9 patients (5.5%).</p><p><strong>Conclusions: </strong>In many HM patients, the temporal progression of aura symptoms was diverse compared to typical descriptions in the literature, and the aura symptoms sustained longer than reported in the population-based study.</p>","PeriodicalId":39292,"journal":{"name":"Clinical Neurology","volume":" ","pages":"338-351"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We present the case of a 69-year-old woman who underwent tracheostomy for advanced amyotrophic lateral sclerosis. The patient was treated with furosemide for leg edema. Body mass index was stable at 21.5 kg/m2. The patient was admitted to our hospital after vomiting because of biliary infection. Fluid therapy with 286 kcal/day of glucose was administered, followed by acute deterioration, including tachycardia (120 bpm), glucose intolerance, abdominal pain, hypophosphatemia (required intravenous phosphate supply; 60 mmol/day), and hypokalemia (required intravenous potassium supply; 60 mEq/day). Refeeding syndrome was suspected, and the patient recovered with adjustments in serum electrolyte levels. We demonstrated that glucose infusion can cause refeeding syndrome in patients with advanced amyotrophic lateral sclerosis without low nutritional intake.
{"title":"[Intravenous glucose infusion may have caused refeeding syndrome in a patient with advanced amyotrophic lateral sclerosis].","authors":"Naoki Yamahara, Nobuaki Yoshikura, Iwasa Yuhei, Takayoshi Shimohata","doi":"10.5692/clinicalneurol.cn-002086","DOIUrl":"10.5692/clinicalneurol.cn-002086","url":null,"abstract":"<p><p>We present the case of a 69-year-old woman who underwent tracheostomy for advanced amyotrophic lateral sclerosis. The patient was treated with furosemide for leg edema. Body mass index was stable at 21.5 kg/m<sup>2</sup>. The patient was admitted to our hospital after vomiting because of biliary infection. Fluid therapy with 286 kcal/day of glucose was administered, followed by acute deterioration, including tachycardia (120 bpm), glucose intolerance, abdominal pain, hypophosphatemia (required intravenous phosphate supply; 60 mmol/day), and hypokalemia (required intravenous potassium supply; 60 mEq/day). Refeeding syndrome was suspected, and the patient recovered with adjustments in serum electrolyte levels. We demonstrated that glucose infusion can cause refeeding syndrome in patients with advanced amyotrophic lateral sclerosis without low nutritional intake.</p>","PeriodicalId":39292,"journal":{"name":"Clinical Neurology","volume":" ","pages":"372-375"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-27Epub Date: 2025-05-09DOI: 10.5692/clinicalneurol.cn-002095
Masami Tanaka
In multiple sclerosis and neuromyelitis optica spectrum disorders, the risk of relapse can no longer be reduced to nearly zero. Consequently, the possibility of misdiagnosis must be considered when a relapse occurs. Nevertheless, managing these conditions requires efforts to minimize the risk of infection and avoid overtreatment. Looking ahead, future treatments may focus not only on enhancing myelin regeneration but also on addressing neuronal and axonal degeneration. Additionally, immune reconstitution therapy-designed to reset and rebuild the immune system's memory-may become a viable option. As such, it will be increasingly important to avoid excessive dosages and to tailor personalized therapies to meet the specific needs of each patient.
{"title":"[Current trends in multiple sclerosis/neuromyelitis optica spectrum disorder therapy: considerations for domestic administration and personalized therapy].","authors":"Masami Tanaka","doi":"10.5692/clinicalneurol.cn-002095","DOIUrl":"10.5692/clinicalneurol.cn-002095","url":null,"abstract":"<p><p>In multiple sclerosis and neuromyelitis optica spectrum disorders, the risk of relapse can no longer be reduced to nearly zero. Consequently, the possibility of misdiagnosis must be considered when a relapse occurs. Nevertheless, managing these conditions requires efforts to minimize the risk of infection and avoid overtreatment. Looking ahead, future treatments may focus not only on enhancing myelin regeneration but also on addressing neuronal and axonal degeneration. Additionally, immune reconstitution therapy-designed to reset and rebuild the immune system's memory-may become a viable option. As such, it will be increasingly important to avoid excessive dosages and to tailor personalized therapies to meet the specific needs of each patient.</p>","PeriodicalId":39292,"journal":{"name":"Clinical Neurology","volume":" ","pages":"319-330"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fatigue is one of the most frequent non-motor symptoms associated with people with Parkinson's disease (PwPD). In this study, we investigated the relationship between fatigue and patients' background characteristics, disease severity, motor and non-motor symptoms, and cognitive and psychological assessments in PwPD. A total of 80 PwPD were included in this study, 40% of whom experienced fatigue. PwPD with fatigue were associated with being female, dyskinesia, and higher levels of levodopa equivalent daily dose, as well as increased severity of depression, apathy and sleep disturbances, in addition to lower quality of life. Fatigue in PwPD is a symptom that warrants clinical attention, as it is linked to multiple risk factors, indicating the need for further intervention studies that incorporate the perspective of personalized medicine.
{"title":"[Factors associated with fatigue in patients with Parkinson's disease].","authors":"Kanako Kurihara, Takayasu Mishima, Koichi Nagaki, Yoshio Tsuboi","doi":"10.5692/clinicalneurol.cn-002061","DOIUrl":"10.5692/clinicalneurol.cn-002061","url":null,"abstract":"<p><p>Fatigue is one of the most frequent non-motor symptoms associated with people with Parkinson's disease (PwPD). In this study, we investigated the relationship between fatigue and patients' background characteristics, disease severity, motor and non-motor symptoms, and cognitive and psychological assessments in PwPD. A total of 80 PwPD were included in this study, 40% of whom experienced fatigue. PwPD with fatigue were associated with being female, dyskinesia, and higher levels of levodopa equivalent daily dose, as well as increased severity of depression, apathy and sleep disturbances, in addition to lower quality of life. Fatigue in PwPD is a symptom that warrants clinical attention, as it is linked to multiple risk factors, indicating the need for further intervention studies that incorporate the perspective of personalized medicine.</p>","PeriodicalId":39292,"journal":{"name":"Clinical Neurology","volume":" ","pages":"331-337"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The patient is a 45-year-old male. He has psoriasis vulgaris and thromboangiitis obliterans (TAO) as a comorbidity and was transferred to our hospital with dysarthria and right hemiparesis. On arrival, he presented with right hemispatial neglect, hemiparesis, and sensory disturbance. Head MRI showed scattered infarctions at the left middle cerebral artery territory, and 3D TOF MRA showed left middle cerebral artery occlusion. We performed mechanical thrombectomy with effective recanalization despite remained residual stenosis. Dual antiplatelet therapy was initiated, and neurological findings gradually improved. No apparent embolic source was identified including antibodies for vasculitis. He was diagnosed with large artery atherosclerosis with psoriasis and TAO as a vascular risk factor. Psoriasis is known to cause atherosclerosis and inflammatory disease by increasing cardiovascular risk. Contrast-enhanced MRI after three months of treatment for psoriasis showed decreased contrast signal at the stenotic lesion.
{"title":"[Early-onset cerebral infarction with psoriasis vulgaris and thromboangiitis obliterans as an athterosclerotic risk factor: a case report].","authors":"Yasunobu Inagaki, Soichiro Abe, Hiroyuki Ishiyama, Takeshi Yoshimoto, Manabu Inoue, Masafumi Ihara","doi":"10.5692/clinicalneurol.cn-002027","DOIUrl":"10.5692/clinicalneurol.cn-002027","url":null,"abstract":"<p><p>The patient is a 45-year-old male. He has psoriasis vulgaris and thromboangiitis obliterans (TAO) as a comorbidity and was transferred to our hospital with dysarthria and right hemiparesis. On arrival, he presented with right hemispatial neglect, hemiparesis, and sensory disturbance. Head MRI showed scattered infarctions at the left middle cerebral artery territory, and 3D TOF MRA showed left middle cerebral artery occlusion. We performed mechanical thrombectomy with effective recanalization despite remained residual stenosis. Dual antiplatelet therapy was initiated, and neurological findings gradually improved. No apparent embolic source was identified including antibodies for vasculitis. He was diagnosed with large artery atherosclerosis with psoriasis and TAO as a vascular risk factor. Psoriasis is known to cause atherosclerosis and inflammatory disease by increasing cardiovascular risk. Contrast-enhanced MRI after three months of treatment for psoriasis showed decreased contrast signal at the stenotic lesion.</p>","PeriodicalId":39292,"journal":{"name":"Clinical Neurology","volume":" ","pages":"359-365"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We report a case of Erdheim-Chester disease (ECD) presenting with recurrent mass lesions that posed significant diagnostic challenges. The patient, a 66-year-old man, had multiple recurrent intracranial lesions with contrast enhancement and edema. Given his history of international travel and partial responsiveness to antibiotics, imported infectious diseases were initially suspected. However, infectious etiology was ruled out based on histopathological examination, leading to a diagnosis of ECD. This case was atypical for ECD due to the imaging findings and recurrent nature of the lesions. When granulomatous lesions with histiocytic infiltration are non-infectious, histiocytic disorders should be considered, and immunohistochemical staining is recommended.
{"title":"[A case of Erdheim-Chester disease with recurrent relapses requiring differentiation from infectious diseases].","authors":"Ryosuke Watanabe, Takuya Hanaoka, Shota Omori, Yui Moroga, Hajime Miyata, Noriyuki Kimura","doi":"10.5692/clinicalneurol.cn-002076","DOIUrl":"10.5692/clinicalneurol.cn-002076","url":null,"abstract":"<p><p>We report a case of Erdheim-Chester disease (ECD) presenting with recurrent mass lesions that posed significant diagnostic challenges. The patient, a 66-year-old man, had multiple recurrent intracranial lesions with contrast enhancement and edema. Given his history of international travel and partial responsiveness to antibiotics, imported infectious diseases were initially suspected. However, infectious etiology was ruled out based on histopathological examination, leading to a diagnosis of ECD. This case was atypical for ECD due to the imaging findings and recurrent nature of the lesions. When granulomatous lesions with histiocytic infiltration are non-infectious, histiocytic disorders should be considered, and immunohistochemical staining is recommended.</p>","PeriodicalId":39292,"journal":{"name":"Clinical Neurology","volume":" ","pages":"352-358"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This manuscript complements the clinical course of the first case of neurosyphilis in our previous report (Kotani. et al. Clin Nuc Med 2024) which highlighted the utility of 18F-THK5351 positron emission tomography (PET), a marker of astrogliosis, to visualize neuroinflammation. The patient was a right-handed man in his early 60s who presented with a three-month history of forgetfulness and subsequent right hemiparesis. Neurological and neuropsychological examinations revealed the right pyramidal signs and impairments in attention, memory, executive function, visuospatial cognition, and verbal fluency. The patient was diagnosed with neurosyphilis based on positive tests for syphilis antibodies in the serum and cerebrospinal fluid (CSF) and elevated CSF cell and protein levels. MRI revealed multiple infarcted lesions that explained the pyramidal signs; however, the lesions responsible for cognitive impairment were not visualized. Two months after penicillin G treatment, the patient exhibited partial improvements in cognitive function, without obvious changes in MRI. To investigate the underlying neuroinflammation associated with astrogliosis, we performed PET imaging after treatment. 18F-THK5351 PET revealed increased uptake and 18F-fluorodeoxyglucose (FDG) PET showed decreased uptake in the left deep frontal white matter and thalamus. We believed that the right pyramidal signs were associated with infarctions contributed by meningovascular syphilis in addition to the arteriosclerosis, whereas cognitive impairment was associated with neuroinflammation due to parenchymal syphilis. Furthermore, the impairment of thalamocortical circuits may have compromised the widespread cortical excitability underlying cognitive impairments. This report highlights the utility of 18F-THK5351 PET imaging in understanding the pathogenesis of neurosyphilis, including cognitive impairment. Further longitudinal studies are required to elucidate the relationship between neuroinflammation and the clinical presentation of neurosyphilis.
这份手稿补充了我们之前报告中第一例神经梅毒的临床过程(Kotani。et al。Clin Nuc Med 2024)强调了18F-THK5351正电子发射断层扫描(PET)的实用性,PET是星形胶质细胞增生的标志,可以可视化神经炎症。患者是一名60岁出头的右撇子,有三个月的健忘和随后的右半瘫病史。神经学和神经心理学检查显示了正确的锥体标志和注意力、记忆、执行功能、视觉空间认知和语言流畅性方面的损伤。根据血清和脑脊液梅毒抗体检测阳性,脑脊液细胞和蛋白水平升高,诊断为神经梅毒。MRI显示多发梗死灶,解释了锥体征象;然而,导致认知障碍的病变并没有被可视化。青霉素G治疗2个月后,患者认知功能部分改善,MRI无明显改变。为了研究与星形胶质细胞增生相关的潜在神经炎症,我们在治疗后进行了PET成像。18F-THK5351 PET显示摄取增加,18f -氟脱氧葡萄糖(FDG) PET显示左侧额叶深部白质和丘脑摄取减少。我们认为,除了动脉硬化外,右锥体征象与脑膜血管梅毒引起的梗死有关,而认知障碍与实质梅毒引起的神经炎症有关。此外,丘脑皮质回路的损伤可能损害了认知障碍背后广泛存在的皮质兴奋性。本报告强调了18F-THK5351 PET成像在了解神经梅毒发病机制(包括认知障碍)中的应用。需要进一步的纵向研究来阐明神经炎症与神经梅毒临床表现之间的关系。
{"title":"Meningovascular and parenchymal neurosyphilis showing more extensive inflammatory lesions on <sup>18</sup>F-THK5351 PET than MRI.","authors":"Risa Kotani, Keiko Hatano, Kenji Ishibashi, Atsushi Iwata","doi":"10.5692/clinicalneurol.cn-002082","DOIUrl":"10.5692/clinicalneurol.cn-002082","url":null,"abstract":"<p><p>This manuscript complements the clinical course of the first case of neurosyphilis in our previous report (Kotani. et al. Clin Nuc Med 2024) which highlighted the utility of <sup>18</sup>F-THK5351 positron emission tomography (PET), a marker of astrogliosis, to visualize neuroinflammation. The patient was a right-handed man in his early 60s who presented with a three-month history of forgetfulness and subsequent right hemiparesis. Neurological and neuropsychological examinations revealed the right pyramidal signs and impairments in attention, memory, executive function, visuospatial cognition, and verbal fluency. The patient was diagnosed with neurosyphilis based on positive tests for syphilis antibodies in the serum and cerebrospinal fluid (CSF) and elevated CSF cell and protein levels. MRI revealed multiple infarcted lesions that explained the pyramidal signs; however, the lesions responsible for cognitive impairment were not visualized. Two months after penicillin G treatment, the patient exhibited partial improvements in cognitive function, without obvious changes in MRI. To investigate the underlying neuroinflammation associated with astrogliosis, we performed PET imaging after treatment. <sup>18</sup>F-THK5351 PET revealed increased uptake and <sup>18</sup>F-fluorodeoxyglucose (FDG) PET showed decreased uptake in the left deep frontal white matter and thalamus. We believed that the right pyramidal signs were associated with infarctions contributed by meningovascular syphilis in addition to the arteriosclerosis, whereas cognitive impairment was associated with neuroinflammation due to parenchymal syphilis. Furthermore, the impairment of thalamocortical circuits may have compromised the widespread cortical excitability underlying cognitive impairments. This report highlights the utility of <sup>18</sup>F-THK5351 PET imaging in understanding the pathogenesis of neurosyphilis, including cognitive impairment. Further longitudinal studies are required to elucidate the relationship between neuroinflammation and the clinical presentation of neurosyphilis.</p>","PeriodicalId":39292,"journal":{"name":"Clinical Neurology","volume":" ","pages":"366-371"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}